)
Visual
test
LB Pharmaceuticals
LB Pharmaceuticals (LBRX) investor relations material
LB Pharmaceuticals Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary26 Mar, 2026
Executive summary
Achieved positive Phase 2 results for LB-102 in acute schizophrenia, supporting further development in neuropsychiatric disorders.
Advanced LB-102 into pivotal Phase 3 (NOVA-2) for schizophrenia and Phase 2 (ILLUMINATE-1) for bipolar depression; planned Phase 2 for adjunctive MDD in 2027.
Completed successful IPO in September 2025, raising $327.8 million, and secured $100 million in private placement in February 2026.
Strengthened leadership with new board and executive appointments to support clinical and corporate strategy.
Financial highlights
Research & development expenses for Q4 2025 were $8.5M, up from $0.4M in Q4 2024, due to new trial start-up costs.
General & administrative expenses for Q4 2025 were $5.4M, slightly up from $5.2M in Q4 2024.
Net loss for Q4 2025 was $11.5M, compared to $5.1M in Q4 2024; full-year 2025 net loss was $25.2M, down from $63.1M in 2024.
Cash, cash equivalents, and marketable securities totaled $295.2M as of December 31, 2025.
Outlook and guidance
Current cash position, including recent private placement, expected to fund operations into Q2 2029.
Topline data from Phase 3 NOVA-2 in schizophrenia expected in H2 2027; Phase 2 ILLUMINATE-1 in bipolar depression expected Q1 2028; Phase 2 adjunctive MDD trial topline data expected H1 2029.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from LB Pharmaceuticals
- LB-102 shows strong efficacy and safety in late-stage trials, targeting major neuropsychiatric markets.LBRX
Investor presentation26 Mar 2026 - LB-102 advances toward pivotal data in major CNS indications, fully funded through 2029.LBRXStifel 2026 Virtual CNS Forum17 Mar 2026
- LB-102 shows strong efficacy and cognitive benefits in late-stage CNS trials, with launch preparations ongoing.LBRXLeerink Global Healthcare Conference 202611 Mar 2026
- LB-102 advances in schizophrenia and bipolar trials, targeting key data by 2028 with strong funding.LBRXStifel 2025 Healthcare Conference3 Feb 2026
- $300M IPO funds phase III schizophrenia and phase II bipolar depression trials, with 2027 data expected.LBRXPiper Sandler 37th Annual Healthcare Conference3 Dec 2025
- IPO raises $228.5M to fund late-stage trials for a novel antipsychotic, but further capital will be needed.LBRXRegistration Filing29 Nov 2025
- IPO aims to fund late-stage trials for a novel antipsychotic, but faces high risk and capital needs.LBRXRegistration Filing29 Nov 2025
- IPO raised $327.8M; $314.5M cash; Q3 net loss $3.6M; LB-102 advances to Phase 3.LBRXQ3 20256 Nov 2025
- LB-102 shows strong efficacy and safety in SCZ, advancing toward pivotal trials in major CNS markets.LBRXCorporate Presentation3 Oct 2025
Next LB Pharmaceuticals earnings date
Q1 20266 May, 2026
LB Pharmaceuticals
Next LB Pharmaceuticals earnings date
Q1 20266 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage